Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
← catalyst calendarSponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-07 | actual | When the study began enrolling |
| Primary completion | 2026-02-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-20 | actual | The whole study's end, after follow-up |
| First posted | 2018-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Melanoma
- Squamous Cell Carcinoma of the Head and Neck
- Non-small Cell Lung Cancer
Interventions
- Biological: Lifileucel — also filed as LN-144, TIL, autologous tumor-infiltrating lymphocytes
- Biological: LN-145 — also filed as TIL, autologous tumor infiltrating lymphocytes
- Drug: Pembrolizumab — also filed as Keytruda
- Biological: LN-145-S1 — also filed as TIL, autologous tumor-infiltrating lymphocytes, PD-1-selected TIL
- Drug: Ipilimumab — also filed as Yervoy
- Drug: Nivolumab — also filed as Opdivo
- Drug: Nivolumab-relatlimab — also filed as Opdualag
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Nab paclitaxel
- Drug: Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFPublications
- PMID 35880942 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed